Clinical Diagnostics

Comprehensive Clinical Test Catalogue

Advanced Diagnostic Solutions for Precision Medicine

NABL-accredited laboratory offering 93 specialized diagnostic tests across 11 clinical specialties. From prenatal genetics to infectious disease detection, we provide accurate, timely results that guide critical healthcare decisions.

93
Diagnostic Tests
11
Specialties
NABL
Accredited
Clinical Laboratory

Prenatal Division

Non-invasive prenatal screening and biochemical marker panels using cfDNA sequencing and immunoassay for early fetal genetic detection.

MDB-PN-001

NIPS-FOCUS

Focused non-invasive prenatal screening targeting the three most common aneuploidies: trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), and trisomy 13 (Patau syndrome). Analyzes cell-free fetal DNA from maternal blood with >99% detection rate.

MethodologyNext-Generation Sequencing of cell-free DNA (cfDNA) from maternal plasma
SampleBlood cfDNA
TAT7-10 Days
MDB-PN-002

NIPS-COMP

Comprehensive non-invasive prenatal screening covering common autosomal aneuploidies (T21, T18, T13) plus sex chromosome aneuploidies (monosomy X, XXY, XYY, XXX). Provides fetal sex determination and expanded aneuploidy detection.

MethodologyNGS-based cfDNA analysis with sex chromosome evaluation
SampleBlood cfDNA
TAT7-10 Days
MDB-PN-003

NIPS-MD

Advanced non-invasive prenatal screening including all common aneuploidies plus microdeletion syndromes (22q11.2 deletion/DiGeorge, 1p36 deletion, Angelman/Prader-Willi, Cri-du-chat, Wolf-Hirschhorn). Highest resolution NIPT available.

MethodologyEnhanced NGS-based cfDNA sequencing with microdeletion detection algorithms
SampleBlood cfDNA
TAT7-10 Days
MDB-PN-004

Double Marker DELFIA

First trimester biochemical screening measuring beta-hCG and PAPP-A combined with nuchal translucency ultrasound for Down syndrome risk assessment. Time-sensitive Dissociation-Enhanced Lanthanide Fluorescence Immunoassay for high sensitivity.

MethodologyDELFIA (Time-Resolved Fluorescence) measuring hCG and PAPP-A
SampleBlood
TAT3 Days
MDB-PN-005

Double Marker PE

Enhanced first trimester screening combining beta-hCG and PAPP-A with placental growth factor (PlGF) for dual assessment of aneuploidy risk and preeclampsia prediction. Enables early intervention strategies for pregnancy complications.

MethodologyDELFIA measuring hCG, PAPP-A, and PlGF
SampleBlood
TAT3 Days
MDB-PN-006

Triple Marker DELFIA

Second trimester maternal serum screening measuring AFP, beta-hCG, and unconjugated estriol (uE3) for neural tube defects and Down syndrome risk assessment. Provides pregnancy-specific risk calculation.

MethodologyDELFIA measuring AFP, hCG, and uE3
SampleBlood
TAT3 Days
MDB-PN-007

Quadruple Marker DELFIA

Enhanced second trimester screening adding inhibin A to triple marker panel for improved Down syndrome and trisomy 18 detection rates. Comprehensive maternal serum screening with highest second trimester sensitivity.

MethodologyDELFIA measuring AFP, hCG, uE3, and Inhibin A
SampleBlood
TAT3 Days